{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Other Investigations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Other blood and lymphatic disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Cardiac disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Gastrointestinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"General disorders and administration site conditions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Infections and infestations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Injury, poisoning and procedural complications"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Metabolism and nutrition disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Musculoskeletal and connective tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Peripheral sensory neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Other nervous system disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Renal and urinary disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Reproductive system and breast disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Respiratory, thoracic and mediastinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Skin and subcutaneous tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Surgical and medical procedures"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Vascular disorders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.","groups":[{"description":"Gemcitabine 50 mg/m2 and Cisplatin 40mg/m2 administered weekly throughout IMRT radiation therapy. Gemcitabine will be infused prior to cisplatin and given over approximately 30 minutes while the cisplatin will be delivered over approximately 60 minutes.","id":"OG000","title":"GEM+CIS+IMRT"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and Treated","reportingStatus":"POSTED","timeFrame":"During treatment period and up to 30 days after stopping the study treatment. The median for duration of study treatment was 2.1 months with a range from 1.2 months to 4.6 months.","title":"Adverse Events (Grade 3 or Higher) During Treatment Period","type":"SECONDARY","unitOfMeasure":"Participants"}